Question 1

What is Durvalumab?

Accepted Answer

Durvalumab is a type of medication known as a monoclonal antibody. It works by targeting specific proteins in the body to help the immune system recognize and destroy cancer cells.

By blocking certain pathways, the drug assists the body's natural defenses in slowing or stopping the growth of tumors.

Question 2

What is Durvalumab used for?

Accepted Answer

Durvalumab is used to treat urothelial carcinoma and non-small cell lung cancer .

Question 3

How does Durvalumab work?

Accepted Answer

Mechanism of Action

Durvalumab belongs to a class of drugs known as PD-L1 inhibitors. It is a monoclonal antibody designed to target specific proteins that cancer cells use to hide from the immune system.

The immune system uses checkpoints to prevent it from attacking healthy cells. Some cancer cells exploit these checkpoints by producing a protein called programmed death-ligand 1 (PD-L1). When PD-L1 binds to certain receptors on T-cells, which are the immune system's primary defense cells, it sends a signal that tells the T-cells not to attack.

Durvalumab works by:

Binding directly to the PD-L1 protein on the surface of cancer cells or other cells within the tumor.

Blocking PD-L1 from interacting with the PD-1 and CD80 receptors on T-cells.

Removing the signal that prevents the immune system from attacking, which allows T-cells to identify and destroy the cancer cells more effectively.

Question 4

What are the brand names for Durvalumab?

Accepted Answer

Durvalumab is sold under the brand name Imfinzi .

Question 5

What are the active ingredients in Durvalumab?

Accepted Answer

The active ingredient in Durvalumab is durvalumab .

Question 6

What are the side effects of Durvalumab?

Accepted Answer

Common side effects of Durvalumab may include:

fatigue

cough

nausea

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Durvalumab?

Accepted Answer

Durvalumab belongs to the PD-L1 inhibitor drug class.

Question 8

What is the dosage of Durvalumab and how do I take it?

Accepted Answer

How Durvalumab is Given

Durvalumab is given as an injection into a vein (intravenous infusion) by a healthcare professional in a medical setting, such as a hospital or clinic. The infusion process usually takes about 60 minutes to complete.

Dosing Schedule

The frequency of treatments depends on the specific condition being treated and how the patient responds to the medication. Common schedules include receiving the medication every two, three, or four weeks. Durvalumab may be used alone or in combination with other cancer treatments, such as chemotherapy.

Missed Doses

If an appointment for an infusion is missed, it is important to contact the healthcare provider right away to reschedule. Maintaining the prescribed schedule is necessary for the medication to be effective.

Question 9

Is Durvalumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Durvalumab can cause harm to a developing fetus. It is important to discuss the risks and benefits with a healthcare provider if you are pregnant or planning to become pregnant. Individuals who can become pregnant should use effective birth control during treatment and for at least 3 months after the last dose of the medication.

Breastfeeding

It is not known whether durvalumab passes into human breast milk. Due to the risk of serious side effects in a nursing child, breastfeeding is not recommended during treatment. Patients are typically advised to wait at least 3 months after their final dose before breastfeeding.

Question 10

What forms and strengths does Durvalumab come in?

Accepted Answer

Available Forms

Durvalumab is supplied as a sterile, preservative-free solution. It is provided in single-dose vials for administration as an intravenous infusion.

Injection: A liquid solution intended for dilution and infusion into a vein.

Question 11

What is the FDA approval status of Durvalumab?

Accepted Answer

FDA Approval Status

Durvalumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various malignancies. It is often used as a first-line treatment or after other therapies, such as chemotherapy and radiation, have been completed.

Approved Indications

The FDA has approved durvalumab for the following uses:

Lung Cancer: It is used for adults with Stage III non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has not worsened after chemoradiation. It is also approved for metastatic NSCLC and small cell lung cancer (SCLC) in both limited and extensive stages.

Gastrointestinal Cancers: It is approved for use in combination with chemotherapy for locally advanced or metastatic biliary tract cancer and for certain types of resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Liver Cancer: It is used to treat unresectable hepatocellular carcinoma, often in combination with other medications.

Bladder Cancer: It is approved for adults with muscle-invasive bladder cancer (MIBC) before and after surgery.

Safety and Monitoring

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required by the FDA for durvalumab. However, regulatory approval is based on its use under the supervision of healthcare professionals experienced in administering cancer therapies.

Question 12

What should I know about Durvalumab and fda approval?

Accepted Answer

FDA-Approved Indications

Durvalumab is approved by the U.S. Food and Drug Administration (FDA) for several types of cancer, often used when the cancer is advanced or has spread.

Lung Cancer

Non-Small Cell Lung Cancer (NSCLC): Approved for adults with Stage III NSCLC that cannot be removed by surgery and has not worsened after treatment with chemotherapy and radiation.

Small Cell Lung Cancer (SCLC): Approved for use with chemotherapy as a first-line treatment for extensive-stage SCLC. It is also approved for limited-stage SCLC in patients whose disease has not progressed following concurrent chemoradiotherapy.

Digestive and Liver Cancers

Biliary Tract Cancer: Approved for use with chemotherapy for adults with locally advanced or metastatic biliary tract cancer.

Liver Cancer: Approved in combination with tremelimumab for adults with unresectable hepatocellular carcinoma.

Gastric and Gastroesophageal Junction (GEJ) Cancers: Approved for use with chemotherapy before surgery and as a single agent after surgery for adults with resectable gastric or GEJ adenocarcinoma.

Bladder Cancer

Durvalumab is approved for use with chemotherapy before surgery and as a single agent after surgery for adults with muscle-invasive bladder cancer.

Durvalumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Approval Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?